trial initiation

Include destruction responsibilities in sponsor-supplier agreements

Maintain a destruction logbook or database

Use validated templates for destruction authorization

2. Authorization Process:

• QA reviews and approves the destruction request
• Confirm reconciliation of the product with site returns and issuance logs
• Obtain destruction authorization from sponsor or Qualified Person (QP)
• Assign trained personnel to oversee the process

Authorization templates and SOP documentation should align with regulatory protocols.

3. Storage and Quarantine Before Destruction:

• Store products under quarantine in a controlled access area
• Label materials clearly as “For Destruction – Do Not Use”
• Ensure environmental conditions (e.g., temperature, humidity) are maintained if applicable
• Log all movement in the quarantine register

4. Transport to Destruction Site:

• Use licensed carriers for pharmaceutical waste
• Apply tamper-evident seals and transport tracking labels
• Document date/time of shipment and courier tracking ID
• Maintain chain-of-custody forms

Transport validation is essential and should be supported by equipment qualification for refrigerated or frozen products.

5. Destruction Execution:

• Conduct at a GMP- or ISO-certified facility licensed for pharmaceutical destruction
• Use appropriate methods: incineration, chemical denaturation, or other approved techniques
• Include trained QA personnel as witnesses
• Record batch numbers, quantity, destruction method, and date

6. Issuance of Destruction Certificate:

• Details all IPs destroyed with batch, kit, and label information
• Signed by site, QA, and destruction site personnel
• Filed in Trial Master File (TMF) and QA archives
• Linked with reconciliation and return logs

Regulatory Considerations:

As per drug regulatory compliance standards, destruction records must be:

• Retained for the applicable trial retention period (e.g., 15–25 years)
• Auditable by health authorities
• Protected against falsification or loss
• In compliance with environmental disposal regulations (e.g., EPA, TGA)

Special Cases: Controlled Substances and Blinded Trials

Controlled Substances:

• Requires DEA or country-specific narcotics agency approval
• Double witness sign-off and secure chain-of-custody
• Separate destruction logs and SOP annexures

Blinded Trials:

• Unblinding should not occur during destruction
• Use code-neutral identification (e.g., Kit ID without treatment group)
• Ensure destruction does not interfere with statistical analysis

Best Practices for IP Destruction:

• Define destruction timelines in the clinical supply plan
• Use barcode/RFID to track kits to destruction
• Conduct periodic audits of destruction records
• Train all staff on SOP adherence and documentation
• Standardize procedures across all sites and depots

Common Mistakes to Avoid:

• Destroying IP without QA approval
• Incomplete or missing destruction certificates
• No chain-of-custody records for transported waste
• Unlabeled or improperly segregated waste material
• Failure to reconcile IP before initiating destruction

Case Study: Destruction of IP in a Phase III Oncology Trial

In a multicenter oncology trial, over 20,000 kits were returned globally. The sponsor developed a centralized destruction SOP. Each kit was reconciled via IRT logs and matched to shipment receipts. Returned IPs were stored in locked quarantine zones until destruction authorization. A third-party vendor conducted incineration under observation. The process yielded signed certificates within 48 hours and passed EMA inspection without observations.

Conclusion:

Destruction of investigational products must be treated with the same rigor as manufacturing and dispensing. Well-documented SOPs, trained personnel, validated processes, and regulatory compliance are the cornerstones of a defensible and effective IP destruction program. Sponsors and sites must collaborate to ensure all expired or unused IP is disposed of in a traceable, safe, and environmentally responsible manner.